🟢 Kura Oncology is trading 6.1% up in pre-market after CEO buys another 100,000 shares

Kura Oncology is trading 6.13% up now at $13.16 after President and CEO Troy Wilson disclosed a second 100,000-share purchase.

• The August 24, 2026 purchase was made at $12.39 per share and was worth approximately $1.24 million; the filing appeared after the regular session.
• Citizens reiterated a Market Outperform rating and $24 price target on August 24.
• Broader futures are modestly positive; no new earnings announcement or regulatory event was identified for August 25, 2026.